Thomas Hedemann, Counsel, Axinn, Veltrop & Harkrider LLP to Speak at TKG's Hatch-Waxman Litigation: The Evolving Legal and Regulatory Framework LIVE Webcast

Top Quote This event is scheduled for September 26, 2017 from 12:00pm – 2:00pm (ET). End Quote
  • (1888PressRelease) September 06, 2017 - The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Thomas Hedemann, Counsel, Axinn, Veltrop & Harkrider LLP will speak at the Knowledge Group’s webcast entitled: “Hatch-Waxman Litigation: The Evolving Legal and Regulatory Framework.”

    For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=2930

    About Thomas Hedemann
    Thomas practices intellectual property litigation with a focus on pharmaceutical (Hatch-Waxman) and medical device patent litigation. He also represents clients in trademark and copyright litigation. His experience ranges across all aspects of litigation from pre-litigation counseling and strategy through fact and expert discovery, dispositive motions and trial. Thomas also has significant appellate experience before the Federal and Second Circuit Courts of Appeals, and is an adjunct professor at the University of Connecticut School of Law. Thomas earned his J.D. from Yale Law School and served as a law clerk to the Honorable Alfred V. Covello of the United States District Court for the District of Connecticut.

    About Axinn, Veltrop & Harkrider LLP
    Axinn is a different kind of law firm. It combines the skills, experience and dedication of the world’s largest firms with the focus, responsiveness, efficiency and attention to client needs of the best boutiques. Axinn was established in the late 1990s by lawyers from premier Wall Street firms with a common vision, and has been joined by lawyers from the best firms and law schools who share that vision. Axinn is devoted to providing the highest conceivable quality of service in three practice areas: antitrust, intellectual property and high-stakes litigation. Axinn achieves that goal with world-class skills and deep trial experience. Time and again, major companies have turned to Axinn for their biggest deals and cases, often on the eve of trial.

    Event Synopsis:
    Congress enacted the Hatch-Waxman Act, formally known as the Drug Price Competition and Patent Term Restoration Act of 1984, P.L. 98-417, to expedite and streamline both generic drug approvals and patent litigation relating to generic drugs. Prior to the adoption of the Act, no streamlined Food and Drug Administration (FDA) approval process existed for generic drugs. Instead, companies seeking to market generic drugs were required to conduct the same kinds of expensive, lengthy clinical trials that drug companies conducted for new brand-named drugs. Additionally, the Act provided a safe harbor to allow generic drug companies to investigate and patent new drugs in order to get FDA approval without the risk of patent infringement liability. See Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984).

    Although the Hatch-Waxman Act has been amended multiple times since its enactment, the underlying structure remains the same, and the number of generic drugs successfully reaching the market has increased dramatically. However, along with the remarkable upsurge in approvals, the ever-changing landscape of Hatch-Waxman litigation creates new risks and challenges for both brand drug sponsor companies and generic companies every day.

    Join a panel of key thought leaders and professionals assembled by The Knowledge Group in a LIVE Webcast as they bring the audience to a road beyond the basics of bringing or defending against Hatch-Waxman Litigation and as they delve into the in-depth analysis of the current trends and recent court rulings surrounding this significant topic. Speakers will also provide the audience with practical strategies in bringing out the best in these lawsuits in a rapidly evolving legal climate.

    Key topics include:
    -Hatch-Waxman Act: Fundamentals
    -Litigation Trends and Pitfalls
    -Recent Court Decisions
    -Scope, Privileges and Limitations
    -Trends, Developments and What Lies Ahead in 2018

    About The Knowledge Group/The Knowledge Congress Live Webcast Series
    The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information